About-cancer/treatment/drugs/caplacizumab-yhdp/zh

卡帕珠單抗

本頁包含有關caplacizumab-yhdp的簡要信息，以及一些鏈接，這些鏈接指向有關該藥物的用途，研究結果和正在進行的臨床試驗的更多信息。

美國品牌名稱

卡布利維

FDA批准

是

該藥物的FDA標籤信息可從DailyMed獲得。

用於癌症

Caplacizumab-yhdp is approved to treat:

• Acquired thrombotic thrombocytopenic purpura (aTTP) in adults. It is used with plasma exchange and immunosuppressive therapy.

More About Caplacizumab-yhdp

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

Clinical Trials Accepting Patients

Find Clinical Trials for Caplacizumab-yhdp - Check for trials from NCI's list of cancer clinical trials now accepting patients.

Important: The drug information on this page is meant to be educational. It is not a substitute for medical advice. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the use of this drug.